KORU Medical Q2 returns to profit on lower manufacturing costs and higher average selling prices
KRMD•Outlook
- KORU Medical narrows 2026 revenue guidance to $47.5-$48.5 mln
- Company raises 2026 gross margin outlook to 62%-64%
- KORU Medical expects international core growth to moderate due to European market launch dynamics
Overview
- U.S. infusion device maker's Q2 revenue rose 18% yr/yr to $12 mln
- Q2 net income improved to $0.25 mln from a loss last year
- Company acquired connected monitoring technology asset to enhance platform
Result drivers
- Core revenue growth - Domestic and international core revenues rose on higher pump and consumable volumes, driven by new patient starts and distributor purchases for pre-filled syringe conversions
- Gross margin improvement - Gross margin increased due to lower manufacturing costs and higher average selling prices
- Pharma services decline - Pharma services and clinical trials revenue fell due to lower clinical trial product revenues related to customer order timing
